Summary

The veterinary vaccines market is projected to reach USD 18.46 billion by 2031, from USD 13.02 billion in 2026, at a CAGR of 7.2%.” during the forecast period.

The growing awareness of animal health, along with the rising pet population and pet ownership, is driving the adoption of veterinary vaccines. Government initiatives aimed at improving animal health and the increasing uptake of pet insurance policies are also contributing to this trend. In major markets like North America and Europe, many pet owners are purchasing pet insurance due to the significant rise in pet care spending in recent years. Additionally, the focus on developing new and advanced vaccine products, combined with the growing adoption of veterinary vaccines in emerging economies, is expected to further support market growth. However, the high costs associated with vaccines may pose a challenge to the veterinary vaccines market's expansion.

“The livestock vaccines segment of veterinary vaccines market to register highest share during the forecast period.”

Based on type, the livestock vaccines segment accounted for the largest share. As livestock animals are owned for the production of food, such as meat and dairy products. As global demand for animal derived food increases and livestock farming intensifies to meet the nutritional needs of an expanding population, there is a greater emphasis on maintaining animal health, preventing disease outbreaks, and improving productivity. Additionally, government regulations, rising awareness about animal health, and growing demand for safer, disease-free food products are driving the adoption of livestock vaccines, further contributing to their dominant share in the market.

“The intramuscular segment to capture the largest market share of veterinary vaccines market.”

Based on route of administration, intramuscular vaccines hold a higher share in the veterinary vaccines market due to their effectiveness and widespread use. Compared to conventional methods of administration like subcutaneous or oral vaccines, this kind of vaccine is delivered directly into the muscle, enabling a faster and more powerful immune response. Because of their ability to produce long-lasting immunity, intramuscular vaccines are frequently used to treat a range of conditions, including bacterial, viral, and parasite infections. The increased market share of intramuscular vaccines is partly a result of their shown efficacy, simplicity of use, and veterinarians' inclination for this approach in both individual pet care and large-scale farming.

“Asia pacific accounted for the fastest growing region of the veterinary vaccines market by region.”
The global veterinary vaccines market is segmented into five major regions, namely, North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. Asia Pacific is the fastest growing market for veterinary vaccines. The increased ownership of pets is a major factor driving the need for veterinary care and vaccinations, particularly in economies like China, India, and Japan. Pet owners are also being encouraged to invest in vaccinations as a result of the region's increasing awareness of animal health and preventative measures. Growing focus on livestock health, better veterinary facilities, and economic expansion all contribute significantly to the market's growth. Governments and organizations have backed animal health initiatives, and more consumers are looking for improved pet healthcare as disposable incomes rise. The Asia Pacific region is becoming a significant growth engine for the veterinary vaccines market due to this confluence of variables.

A breakdown of the primary participants referred to for this report is provided below:
・By Company Type: Tier 1–35%, Tier 2–40%, and Tier 3– 25%
・By Designation: Directors–25%, Managers–50% and Others–25%
・By Region: North America–35%, Europe–30%, Asia Pacific–15% and RoW–20%

The major players operating in the veterinary vaccines market market are Zoetis(US), Merck & Co, Inc. (US), Boehringer Ingelheim International GmbH (Germany), Elanco (US), Virbac (France), Ceva (France), Phibro Animal Health Corporation (US), Hester Biosciences Limited (India), Neogen Corporation (US), HIPRA (Spain), Biogénesis Bagó (Argentina), Tianjin Ringpu BioTechnology Co., Ltd. (China), China Animal Husbandry Industry Co., LTD. (China), Jinyu Bio-technology Co., Ltd. (China), and Vaxxinova International B.V.(Netherlands).

Research Coverage

This report studies the veterinary vaccines market based on type, disease, technology, route of administration and region. The report also studies factors (such as drivers, restraints, opportunities, and challenges) affecting market growth and provides details of the competitive landscape for market leaders. Furthermore, the report analyzes micro markets with respect to their individual growth trends and forecasts the revenue of the market segments with respect to five major regions (and the respective countries in these regions).

Reasons to Buy the Report
The report will enable established firms as well as entrants/smaller firms to gauge the pulse of the market, which, in turn, would help them to garner a larger market share. Firms purchasing the report could use one or a combination of the below-mentioned strategies for strengthening their market presence.

This report provides insights on the following pointers:
・ Analysis of Key divers (increased companion animal population and pet ownership, growing incidence of infectious disease, government initiatives to improve animal health), restraints (high cost associated with vaccines), Opportunities (emerging markets, technological advancement and developments) , Challenge (limited awareness and shortage of veterinarians, stringent regulatory requirements)
・ Market Penetration: Comprehensive information on the product portfolios offered by the top players in the veterinary vaccines market
・ Product Development/Innovation: Detailed insights on the upcoming trends, R&D activities, and product launches in the veterinary vaccines market
・ Market Development: Comprehensive information on lucrative emerging regions
・ Market Diversification: Exhaustive information about new products, growing geographies, and recent developments in the veterinary vaccines market
・ Competitive Assessment: In-depth assessment of market segments, growth strategies, revenue analysis, and products of the leading market players.

ページTOPに戻る

Table of Contents

1 INTRODUCTION 35
1.1 STUDY OBJECTIVES 35
1.2 MARKET DEFINITION 36
1.3 STUDY SCOPE 36
1.3.1 MARKETS COVERED & REGIONAL SCOPE 36
1.3.2 INCLUSIONS & EXCLUSIONS 37
1.3.3 YEARS CONSIDERED 38
1.4 CURRENCY CONSIDERED 38
1.5 LIMITATIONS 38
1.6 STAKEHOLDERS 39
1.7 SUMMARY OF CHANGES 39
2 EXECUTIVE SUMMARY 40
2.1 MARKET HIGHLIGHTS & KEY INSIGHTS 40
2.2 KEY MARKET PARTICIPANTS: MAPPING OF STRATEGIC DEVELOPMENTS 41
2.3 DISRUPTIVE TRENDS IN VETERINARY VACCINES MARKET 42
2.4 HIGH-GROWTH SEGMENTS 43
2.5 REGIONAL SNAPSHOT: MARKET SIZE, GROWTH RATE, AND FORECAST 44
3 PREMIUM INSIGHTS 45
3.1 VETERINARY VACCINES MARKET OVERVIEW 45
3.2 ASIA PACIFIC: VETERINARY VACCINES MARKET, BY COUNTRY AND END USER 46
3.3 GEOGRAPHIC SNAPSHOT OF VETERINARY VACCINES MARKET 47
4 MARKET OVERVIEW 48
4.1 INTRODUCTION 48
4.2 MARKET DYNAMICS 48
4.2.1 DRIVERS 49
4.2.1.1 Increase in companion animal population and pet ownership 49
4.2.1.2 Increasing incidence of infectious and zoonotic diseases 51
4.2.1.3 Favorable initiatives by government agencies and animal health organizations 51
4.2.1.4 Growing demand for animal-derived food products 52
4.2.1.5 Increasing pet insurance penetration and animal health expenditure 54
4.2.2 RESTRAINTS 55
4.2.2.1 High cost of veterinary vaccine development, manufacturing, and cold-chain distribution 55
4.2.3 OPPORTUNITIES 56
4.2.3.1 Advancements in vaccine technologies and strategic collaborations 56
4.2.3.2 Untapped opportunities in emerging livestock and companion animal markets 57
4.2.4 CHALLENGES 57
4.2.4.1 Limited awareness, training gaps, and shortage of veterinary professionals in low-income countries 57
4.2.4.2 Stringent regulatory pathways and complex approval frameworks 58
4.3 UNMET NEEDS & WHITE SPACES 58
4.3.1 UNMET NEEDS IN VETERINARY VACCINES MARKET 58
4.3.2 WHITE SPACE OPPORTUNITIES 59
4.4 INTERCONNECTED MARKETS & CROSS-SECTOR OPPORTUNITIES 60
4.4.1 INTERCONNECTED MARKETS 60
4.4.2 CROSS-SECTOR OPPORTUNITIES 61
4.5 STRATEGIC MOVES BY TIER 1/2/3 PLAYERS 61
4.5.1 STRATEGIC MOVES IN VETERINARY VACCINES MARKET 61
5 INDUSTRY TRENDS 63
5.1 PORTER’S FIVE FORCES ANALYSIS 63
5.1.1 THREAT OF NEW ENTRANTS 64
5.1.2 THREAT OF SUBSTITUTES 64
5.1.3 BARGAINING POWER OF SUPPLIERS 65
5.1.4 BARGAINING POWER OF BUYERS 65
5.1.5 INTENSITY OF COMPETITIVE RIVALRY 65
5.2 MACROECONOMIC INDICATORS 66
5.2.1 INTRODUCTION 66
5.2.2 GDP TRENDS & FORECAST 66
5.2.3 TRENDS IN GLOBAL ANIMAL HEALTH INDUSTRY 67
5.2.4 TRENDS IN GLOBAL VETERINARY BIOLOGICS INDUSTRY 67
5.3 SUPPLY CHAIN ANALYSIS 67
5.4 VALUE CHAIN ANALYSIS 69
5.5 ECOSYSTEM ANALYSIS 70
5.5.1 MANUFACTURERS 71
5.5.2 END USERS 72
5.5.3 REGULATORY BODIES 72
5.6 PRICING ANALYSIS 73
5.6.1 AVERAGE SELLING PRICE TREND OF VETERINARY VACCINES, BY KEY PLAYER, 2023–2025 74
5.6.2 AVERAGE SELLING PRICE TREND OF VETERINARY VACCINES, BY ROUTE OF ADMINISTRATION, 2023–2025 75
5.6.3 AVERAGE SELLING PRICE TREND OF VETERINARY VACCINES, BY END USER, 2023–2025 76
5.6.4 AVERAGE SELLING PRICE TREND OF VETERINARY VACCINES, BY REGION, 2023–2025 77
5.7 TRADE ANALYSIS 77
5.7.1 IMPORT DATA (HS CODE 3002) 78
5.7.2 EXPORT DATA FOR (HS CODE 3002) 78
5.8 REIMBURSEMENT SCENARIO 79
5.9 KEY CONFERENCES & EVENTS, 2026–2027 79
5.10 TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS 80
5.11 INVESTMENT & FUNDING SCENARIO 81
5.12 CASE STUDY ANALYSIS 82
5.13 IMPACT OF 2025 US TARIFFS ON VETERINARY VACCINES MARKET 83
5.13.1 INTRODUCTION 83
5.13.2 KEY TARIFF RATES 84
5.13.3 PRICE IMPACT ANALYSIS 85
5.13.4 IMPACT ON COUNTRY/REGION 86
5.13.5 IMPACT ON END-USE SEGMENTS 87
5.13.5.1 Veterinary Hospitals 87
5.13.5.2 Veterinary Clinics 88
5.13.5.3 Other End Users (Veterinary Research Organizations, Government Vaccination Centers) 88
6 TECHNOLOGICAL ADVANCEMENTS, AI-DRIVEN IMPACT, PATENTS, INNOVATIONS, AND FUTURE APPLICATIONS 89
6.1 TECHNOLOGY ANALYSIS 89
6.1.1 KEY EMERGING TECHNOLOGIES 89
6.1.1.1 Recombinant DNA technology 89
6.1.1.2 mRNA-based vaccines 89
6.1.2 COMPLEMENTARY TECHNOLOGIES 90
6.1.2.1 Vaccine adjuvant technology 90
6.1.2.2 Needle-free & microneedle technology 90
6.1.3 ADJACENT TECHNOLOGIES 90
6.1.3.1 Genome editing technology 90
6.2 TECHNOLOGY/PRODUCT ROADMAP 91
6.2.1 NEAR TERM (2025–2027) 91
6.2.2 MID TERM (2028–2030) 91
6.2.3 LONG TERM (2030+) 92
6.3 PATENT ANALYSIS 92
6.3.1 JURISDICTION & TOP APPLICANT ANALYSIS 92
6.4 FUTURE APPLICATIONS 96
6.4.1 AI-ENABLED & DATA-DRIVEN PROCEDURE OPTIMIZATION 97
6.4.2 PERSONALIZED & PRECISION VACCINATION 97
6.4.3 CONNECTED ANIMAL HEALTH ECOSYSTEMS & DIGITAL INTEGRATION 97
6.5 IMPACT OF AI/GEN AI ON VETERINARY VACCINES MARKET 97
6.5.1 INTRODUCTION 97
6.5.2 MARKET POTENTIAL OF AI IN VETERINARY VACCINES 98
6.5.3 AI USE CASES 99
6.5.3.1 Vaccine Discovery and Antigen Identification 99
6.5.3.2 Disease Surveillance and Outbreak Prediction 99
6.5.3.3 Vaccine Formulation and Manufacturing Optimization 99
6.5.3.4 Precision Vaccination and Herd Health Management 99
6.5.3.5 Regulatory Intelligence and Scientific Workflow Automation 99
6.5.4 KEY COMPANIES IMPLEMENTING AI 100
7 SUSTAINABILITY & REGULATORY LANDSCAPE 102
7.1 REGIONAL REGULATIONS & COMPLIANCE 102
7.1.1 REGULATORY ANALYSIS 102
7.1.2 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 103
7.1.2.1 North America 103
7.1.2.2 Europe 104
7.1.2.3 Rest of the world 105
7.1.3 INDUSTRY STANDARDS 106
7.2 SUSTAINABILITY INITIATIVES 107
7.2.1 RECYCLED & ECO-FRIENDLY MATERIALS FOR VETERINARY VACCINES 107
7.2.2 SUSTAINABILITY IMPACT & REGULATORY POLICY INITIATIVES 107
7.2.3 CERTIFICATIONS, LABELING, AND ECO-STANDARDS 108
8 CUSTOMER LANDSCAPE & BUYER BEHAVIOR 109
8.1 KEY STAKEHOLDERS & BUYING CRITERIA 109
8.1.1 KEY STAKEHOLDERS IN BUYING PROCESS 109
8.1.2 BUYING CRITERIA 110
8.2 CUSTOMER LANDSCAPE & BUYER BEHAVIOR 111
8.2.1 DECISION-MAKING PROCESS 111
8.2.2 ADOPTION BARRIERS & INTERNAL CHALLENGES 112
8.2.3 UNMET NEEDS FROM VARIOUS END-USE INDUSTRIES 113
8.2.4 MARKET PROFITABILITY 113
9 VETERINARY VACCINES MARKET, BY TYPE 115
9.1 INTRODUCTION 116
9.2 LIVESTOCK VACCINES 116
9.2.1 BOVINE VACCINES 118
9.2.1.1 Increasing demand for meat and milk to drive market 118
9.2.1.2 Global volume analysis of bovine vaccines, 2024–2031 (thousand units) 120
9.2.2 SMALL RUMINANT VACCINES 120
9.2.2.1 Increased livestock population and favorable government initiatives to propel market growth 120
9.2.2.2 Global volume analysis of small ruminant vaccines, 2024–2031 (thousand units) 123
 
9.3 PORCINE VACCINES 123
9.3.1 GROWING AWARENESS ABOUT ANIMAL VACCINATION TO SUPPORT MARKET GROWTH 123
9.3.1.1 Global volume analysis of porcine vaccines, 2024–2031 (thousand units) 126
9.4 POULTRY VACCINES 126
9.4.1 HIGH NEED FOR PROTEIN IN DAILY DIET TO AUGMENT MARKET GROWTH 126
9.4.1.1 Global volume analysis of poultry vaccines, 2024–2031 (thousand units) 129
9.5 COMPANION ANIMAL VACCINES 129
9.5.1 CANINE VACCINES 131
9.5.1.1 Increasing number of pet dogs and growing prevalence of zoonotic diseases to spur market growth 131
9.5.1.2 Global volume analysis of Canine vaccines, 2024–2031(thousand units) 133
9.5.2 FELINE VACCINES 133
9.5.2.1 Rising adoption of cats and growing need for better veterinary care to boost market growth 133
9.5.2.2 Global volume analysis of feline vaccines, 2024–2031 (thousand units) 135
9.6 AQUACULTURE VACCINES 135
9.6.1 INCREASED POPULARITY OF COMMERCIAL FISH FARMING TO FUEL MARKET GROWTH 135
9.6.1.1 Global volume analysis of aquaculture vaccines, 2024–2031 (thousand units) 137
9.7 OTHER VETERINARY VACCINES 137
10 VETERINARY VACCINES MARKET, BY DISEASE 139
10.1 INTRODUCTION 140
10.2 LIVESTOCK DISEASES 140
10.2.1 BOVINE DISEASES 142
10.2.1.1 Increasing government support to aid the market growth 142
10.2.2 SMALL RUMINANT DISEASES 143
10.2.2.1 Growing ruminant vaccines demand to propel the market growth 143
10.3 PORCINE DISEASES 144
10.3.1 PORCINE DISEASES TO ACCOUNT FOR LARGEST SHARE 144
10.4 POULTRY DISEASES 145
10.4.1 GROWING GOVERNMENT PROGRAMME TO CONTROL POULTRY DISEASES 145
10.5 COMPANION ANIMAL DISEASES 147
10.5.1 CANINE DISEASES 148
10.5.1.1 Innovative canine vaccine development to 148
10.5.2 FELINE DISEASES 149
10.5.2.1 Feline disease segment to grow at highest CAGR during forecast period 149
 
10.6 AQUACULTURE DISEASES 150
10.6.1 GROWING FOCUS ON DEVELOPING AQUACULTURE VACCINES 150
10.7 OTHER DISEASES 152
11 VETERINARY VACCINES MARKET, BY TECHNOLOGY 153
11.1 INTRODUCTION 154
11.2 LIVE ATTENUATED VACCINES 154
11.2.1 EASE OF ADMINISTRATION AND LONG-TERM IMMUNITY TO SUPPORT MARKET GROWTH 154
11.3 INACTIVATED VACCINES 155
11.3.1 NEED TO DEVELOP ARTIFICIAL IMMUNITY FROM NON-LIVING PATHOGENS TO DRIVE MARKET 155
11.4 TOXOID VACCINES 157
11.4.1 TOXOID VACCINES TO STIMULATE IMMUNE SYSTEM AND PROTECT ANIMALS FROM BACTERIAL TOXINS 157
11.5 RECOMBINANT VACCINES 158
11.5.1 BETTER STABILITY, HIGHER SAFETY, AND NO POST-VACCINATION REACTIONS TO SUPPORT VACCINE ADOPTION 158
11.6 OTHER VACCINE TECHNOLOGIES 159
12 VETERINARY VACCINES MARKET, BY ROUTE OF ADMINISTRATION 160
12.1 INTRODUCTION 161
12.2 SUBCUTANEOUS ROUTE OF ADMINISTRATION 163
12.2.1 EASE OF ADMINISTRATION, REDUCED PAIN, AND LOWER RISK OF TISSUE DAMAGE TO AID MARKET GROWTH 163
12.3 INTRAMUSCULAR ROUTE OF ADMINISTRATION 165
12.3.1 BETTER IMMUNE RESPONSE AND LOWER RATE OF INJECTION-SITE REACTIONS TO AUGMENT MARKET GROWTH 165
12.4 ORAL ROUTE OF ADMINISTRATION 167
12.4.1 COST-EFFECTIVENESS, INCREASED SAFETY, AND HIGH PATIENT ACCEPTABILITY TO SUPPORT MARKET GROWTH 167
12.5 INTRANASAL/SPRAY ROUTE OF ADMINISTRATION 169
12.5.1 COST-EFFECTIVENESS AND RAPID ABSORPTION OF MEDICINE TO AID IN MASS VACCINATION 169
12.6 INTRAOCULAR ROUTE OF ADMINISTRATION 171
12.6.1 SIMPLE ADMINISTRATION OF VACCINES IN LARGE-SCALE FARMING OPERATIONS TO AID MARKET GROWTH 171
12.7 OTHER ROUTES OF ADMINISTRATION 173
13 VETERINARY VACCINES MARKET, BY END USER 175
13.1 INTRODUCTION 176
13.2 VETERINARY HOSPITALS 176
13.2.1 GROWING AWARENESS ABOUT ANIMAL HEALTH AND INCREASING VETERINARY EXPENDITURE BY PET OWNERS TO DRIVE MARKET 176
 
13.3 VETERINARY CLINICS 178
13.3.1 RISING NUMBER OF PET VISITS TO PRIVATE CLINICS TO SPUR MARKET GROWTH 178
13.4 OTHER END USERS 180
14 VETERINARY VACCINES MARKET, BY REGION 181
14.1 INTRODUCTION 182
14.2 NORTH AMERICA 182
14.2.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA 183
14.2.2 NORTH AMERICA: VOLUME ANALYSIS OF VETERINARY VACCINES, BY TYPE, 2024–2031(THOUSAND UNITS) 184
14.2.3 US 188
14.2.3.1 US to dominate North American veterinary vaccines market during forecast period 188
14.2.4 CANADA 192
14.2.4.1 Rising pet ownership and increasing chicken consumption to drive demand for veterinary vaccines 192
14.3 EUROPE 196
14.3.1 EUROPE: VOLUME ANALYSIS OF VETERINARY VACCINES, BY TYPE, 2024–2031(THOUSAND UNITS) 197
14.3.2 MACROECONOMIC OUTLOOK FOR EUROPE 201
14.3.3 GERMANY 202
14.3.3.1 Increased poultry consumption and high pet healthcare expenditure to drive market 202
14.3.4 UK 206
14.3.4.1 Rising adoption of pets to augment market growth 206
14.3.5 FRANCE 210
14.3.5.1 Rising companion animal and livestock population to boost market growth 210
14.3.6 ITALY 214
14.3.6.1 Better availability of pet products through large-scale outlets to augment market growth 214
14.3.7 SPAIN 218
14.3.7.1 Increase in veterinary practices and willingness to spend on animal healthcare to drive market 218
14.3.8 NETHERLANDS 222
14.3.8.1 High-density livestock production and strong biosecurity standards to drive market growth 222
14.3.9 REST OF EUROPE 227
14.4 ASIA PACIFIC 232
14.4.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC 232
14.4.2 ASIA PACIFIC: VOLUME ANALYSIS OF VETERINARY VACCINES, BY TYPE, 2024–2031(THOUSAND UNITS) 233
14.4.3 CHINA 238
14.4.3.1 Increasing companion animal population and growing incidence of zoonotic diseases to drive market 238
14.4.4 JAPAN 242
14.4.4.1 High consumption of animal-derived products and increased pet health expenditure to propel market growth 242
14.4.5 INDIA 246
14.4.5.1 Growth in poultry industry and high demand for dairy products to augment market growth 246
14.4.6 AUSTRALIA 250
14.4.6.1 Increase in per capita income and rise in meat consumption to aid market growth 250
14.4.7 SOUTH KOREA 254
14.4.7.1 High demand for animal protein and favorable government subsidies for meat production to spur market growth 254
14.4.8 REST OF ASIA PACIFIC 259
14.5 LATIN AMERICA 263
14.5.1 LATIN AMERICA: VOLUME ANALYSIS OF VETERINARY VACCINES, BY TYPE, 2024–2031(THOUSAND UNITS) 264
14.5.2 MACROECONOMIC OUTLOOK FOR LATIN AMERICA 268
14.5.3 BRAZIL 269
14.5.3.1 Well-established livestock industry to promote market growth 269
14.5.4 MEXICO 273
14.5.4.1 Focus on pork and poultry meat production to fuel market growth 273
14.5.5 REST OF LATIN AMERICA 277
14.6 MIDDLE EAST & AFRICA 281
14.6.1 MIDDLE EAST & AFRICA: VOLUME ANALYSIS OF VETERINARY VACCINES, BY TYPE, 2024–2031(THOUSAND UNITS) 282
14.6.2 MACROECONOMIC OUTLOOK FOR MIDDLE EAST & AFRICA 286
14.6.3 GCC COUNTRIES 287
14.6.3.1 Kingdom of Saudi Arabia 291
14.6.3.1.1 Favorable government initiatives for better animal health infrastructure to propel market growth 291
14.6.3.2 UAE 296
14.6.3.2.1 Favorable government initiatives to safeguard national livestock population and support sustainable agriculture 296
14.6.3.3 Rest of GCC countries 300
14.6.4 REST OF MIDDLE EAST & AFRICA 305
15 COMPETITIVE LANDSCAPE 310
15.1 INTRODUCTION 310
15.2 KEY PLAYER COMPETITIVE STRATEGIES/RIGHT TO WIN, 2024–2026 311
15.2.1 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN VETERINARY VACCINES MARKET 311
15.3 REVENUE ANALYSIS, 2023–2025 313
15.4 MARKET SHARE ANALYSIS, 2025 314
15.4.1 GLOBAL MARKET SHARE ANALYSIS (2025) 314
 
15.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2025 316
15.5.1 STARS 316
15.5.2 EMERGING LEADERS 316
15.5.3 PERVASIVE PLAYERS 316
15.5.4 PARTICIPANTS 316
15.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2025 318
15.5.5.1 Company footprint 318
15.5.5.2 Type footprint 319
15.5.5.3 Disease footprint 320
15.5.5.4 Technology footprint 321
15.5.5.5 Route of administration footprint 322
15.5.5.6 Region footprint 323
15.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2025 324
15.6.1 PROGRESSIVE COMPANIES 324
15.6.2 RESPONSIVE COMPANIES 324
15.6.3 DYNAMIC COMPANIES 324
15.6.4 STARTING BLOCKS 324
15.6.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2025 326
15.6.5.1 Detailed list of key startups/SMEs 326
15.6.5.2 Competitive benchmarking of key startups/SMEs 327
15.7 COMPANY VALUATION & FINANCIAL METRICS 328
15.7.1 FINANCIAL METRICS 328
15.7.2 COMPANY VALUATION 328
15.8 BRAND/PRODUCT COMPARISON 329
15.9 COMPETITIVE SCENARIO 330
15.9.1 PRODUCT LAUNCHES & APPROVALS 330
15.9.2 DEALS 331
15.9.3 EXPANSIONS 331
15.9.4 OTHER DEVELOPMENTS 332
16 COMPANY PROFILES 333
16.1 KEY PLAYERS 333
16.1.1 MERCK & CO., INC. 333
16.1.1.1 Business overview 333
16.1.1.2 Products offered 335
16.1.1.3 Recent developments 338
16.1.1.3.1 Product launches & approvals 338
16.1.1.3.2 Deals 339
16.1.1.3.3 Expansions 339
16.1.1.4 MnM view 339
16.1.1.4.1 Right to win 339
16.1.1.4.2 Strategic choices 339
16.1.1.4.3 Weaknesses & competitive threats 339
16.1.2 ZOETIS SERVICES LLC 340
16.1.2.1 Business overview 340
16.1.2.2 Products offered 341
16.1.2.3 Recent developments 343
16.1.2.3.1 Product approvals 343
16.1.2.3.2 Deals 343
16.1.2.3.3 Expansions 343
16.1.2.3.4 Other developments 344
16.1.2.4 MnM view 344
16.1.2.4.1 Right to win 344
16.1.2.4.2 Strategic choices 344
16.1.2.4.3 Weaknesses & competitive threats 344
16.1.3 BOEHRINGER INGELHEIM INTERNATIONAL GMBH 345
16.1.3.1 Business overview 345
16.1.3.2 Products offered 346
16.1.3.3 Recent developments 347
16.1.3.3.1 Product launches 347
16.1.3.3.2 Expansions 348
16.1.3.4 MnM view 348
16.1.3.4.1 Right to win 348
16.1.3.4.2 Strategic choices 348
16.1.3.4.3 Weaknesses & competitive threats 348
16.1.4 ELANCO 349
16.1.4.1 Business overview 349
16.1.4.2 Products offered 350
16.1.4.3 Recent developments 352
16.1.4.3.1 Product approvals 352
16.1.4.3.2 Deals 352
16.1.4.4 MnM view 353
16.1.4.4.1 Right to win 353
16.1.4.4.2 Strategic choices 353
16.1.4.4.3 Weaknesses & competitive threats 353
16.1.5 VIRBAC 354
16.1.5.1 Business overview 354
16.1.5.2 Products offered 356
16.1.5.3 Recent developments 357
16.1.5.3.1 Product launches 357
16.1.5.3.2 Deals 358
16.1.5.3.3 Expansions 358
16.1.5.4 MnM view 359
16.1.5.4.1 Right to win 359
16.1.5.4.2 Strategic choices 359
16.1.5.4.3 Weaknesses & competitive threats 359
16.1.6 CEVA 360
16.1.6.1 Business overview 360
16.1.6.2 Products offered 360
16.1.6.3 Recent developments 362
16.1.6.3.1 Product launches 362
16.1.6.3.2 Expansions 362
16.1.7 PHIBRO ANIMAL HEALTH CORPORATION 363
16.1.7.1 Business overview 363
16.1.7.2 Products offered 364
16.1.8 HESTER BIOSCIENCES LIMITED 366
16.1.8.1 Business overview 366
16.1.8.2 Products offered 367
16.1.8.3 Recent developments 369
16.1.8.3.1 Product approvals 369
16.1.8.3.2 Deals 369
16.1.9 NEOGEN CORPORATION 370
16.1.9.1 Business overview 370
16.1.9.2 Products offered 371
16.1.9.3 Recent developments 372
16.1.9.3.1 Deals 372
16.1.10 HIPRA 373
16.1.10.1 Business overview 373
16.1.10.2 Products offered 373
16.1.10.3 Recent developments 375
16.1.10.3.1 Product launches 375
16.1.10.3.2 Deals 376
16.1.11 BIOGÉNESIS BAGÓ 377
16.1.11.1 Business overview 377
16.1.11.2 Products offered 377
16.1.11.3 Recent developments 378
16.1.11.3.1 Deals 378
16.1.11.3.2 Expansions 378
16.1.12 TIANJIN RINGPU BIO-TECHNOLOGY CO., LTD. 379
16.1.12.1 Business overview 379
16.1.12.2 Products offered 380
16.1.13 CHINA ANIMAL HUSBANDRY INDUSTRY CO., LTD. 382
16.1.13.1 Business overview 382
16.1.13.2 Products offered 382
16.1.13.2.1 Other developments 384
 
16.1.14 JINYU BIOTECHNOLOGY CO., LTD. 385
16.1.14.1 Business overview 385
16.1.14.2 Products offered 385
16.1.14.3 Recent developments 387
16.1.14.3.1 Product approvals 387
16.1.15 VAXXINOVA INTERNATIONAL B.V. 388
16.1.15.1 Business overview 388
16.1.15.2 Products offered 388
16.1.15.3 Recent developments 390
16.1.15.3.1 Product approvals 390
16.1.15.3.2 Deals 390
16.1.15.3.3 Expansions 391
16.2 OTHER COMPANIES 392
16.2.1 ENDOVAC ANIMAL HEALTH REBRAND CA 392
16.2.2 BRILLIANT BIO PHARMA PRIVATE LIMITED 393
16.2.3 APTIMMUNE 394
16.2.4 INDIAN IMMUNOLOGICALS LTD. 395
16.2.5 TORIGEN 396
16.2.6 INTAS PHARMACEUTICALS LTD. 396
16.2.7 OUROFINO S.A 397
16.2.8 BIOVAC LTD. 398
16.2.9 LABORATOIRE LCV 399
16.2.10 KYORITSU SEIYAKU CORPORATION 400
17 RESEARCH METHODOLOGY 401
17.1 RESEARCH DATA 401
17.1.1 SECONDARY DATA 401
17.1.1.1 Key data from secondary sources 403
17.1.2 PRIMARY DATA 404
17.1.2.1 Key data from primary sources 405
17.1.2.2 Key industry insights 405
17.1.2.3 Breakdown of primary interviews 406
17.1.2.4 Key industry insights 407
17.2 MARKET SIZE ESTIMATION 407
17.2.1 APPROACH 1: COMPANY REVENUE ANALYSIS APPROACH 408
17.2.2 APPROACH 2: CUSTOMER-BASED MARKET ESTIMATION 410
17.2.3 APPROACH 3: BOTTOM APPROACH 411
17.2.4 APPROACH 4: TOP-DOWN 411
17.2.5 BASE NUMBER CALCULATION 412
17.2.6 COMPANY PRESENTATIONS 412
17.2.7 PRIMARY INTERVIEWS 412
17.2.8 APPROACH 5: VOLUME ESTIMATION 412
17.2.9 APPROACH 6: DEMAND-SIDE 412
17.3 MARKET BREAKDOWN AND DATA TRIANGULATION 417
17.4 MARKET SHARE ASSESSMENT 418
17.5 RESEARCH ASSUMPTIONS 418
17.5.1 STUDY ASSUMPTIONS 418
17.5.2 GROWTH RATE ASSUMPTIONS 418
17.6 RISK ASSESSMENT 419
17.6.1 RESEARCH LIMITATIONS 419
18 APPENDIX 420
18.1 DISCUSSION GUIDE 420
18.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 426
18.3 CUSTOMIZATION OPTIONS 428
18.4 RELATED REPORTS 428
18.5 AUTHOR DETAILS 429